Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Microbial-Based Therapies in the Treatment of Inflammatory Bowel Disease - An Overview of Human Studies

Full text
Author(s):
Basso, Paulo Jose [1] ; Saraiva Camara, Niels Olsen [1] ; Sales-Campos, Helioswilton [2]
Total Authors: 3
Affiliation:
[1] Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Sao Paulo - Brazil
[2] Univ Fed Goias, Inst Trop Pathol & Publ Hlth, Goiania, Go - Brazil
Total Affiliations: 2
Document type: Review article
Source: FRONTIERS IN PHARMACOLOGY; v. 9, JAN 10 2019.
Web of Science Citations: 10
Abstract

Inflammatory bowel disease (IBD) is a group of multifactorial and inflammatory infirmities comprised of two main entities: Ulcerative colitis (UC) and Crohn's disease (CD). Classic strategies to treat IBD are focused on decreasing inflammation besides inducing and extending disease remission. However, these approaches have several limitations such as low responsiveness, excessive immunosuppression, and refractoriness. Despite the multifactorial causality of IBD, immune disturbances and intestinal dysbiosis have been suggested as the central players in disease pathogenesis. Hence, therapies aiming at modulating intestinal microbial composition may represent a promising strategy in IBD control. Fecal microbiota transplantation (FMT) and probiotics have been explored as promising candidates to reestablish microbial balance in several immune-mediated diseases such as IBD. These microbial-based therapies have demonstrated the ability to reduce both the dysbiotic environment and production of inflammatory mediators, thus inducing remission, especially in UC. Despite these promising results, there is still no consensus on the relevance of such treatments in IBD as a potential clinical strategy. Thus, this review aims to critically review and describe the use of FMT and probiotics to treat patients with IBD. (AU)

FAPESP's process: 17/05264-7 - Cell metabolism, microbiota and immune system: new paradigms in renal diseases physiopathology
Grantee:Niels Olsen Saraiva Câmara
Support Opportunities: Research Projects - Thematic Grants
FAPESP's process: 15/26682-6 - Evaluation of mTOR on energy metabolism and activation of B cells during experimental intestinal inflammation
Grantee:Paulo José Basso
Support Opportunities: Scholarships in Brazil - Doctorate